Stratos Wealth Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.84M | Sell |
76,265
-3,546
| -4% | -$92.8K | 0.1% | 199 |
|
|
2026
Q1 | $2.24M | Buy |
79,811
+8,190
| +11% | +$218K | 0.14% | 151 |
|
|
2025
Q4 | $1.78M | Buy |
71,621
+4,872
| +7% | +$123K | 0.09% | 228 |
|
|
2025
Q3 | $1.7M | Sell |
66,749
-1,644
| -2% | -$40.6K | 0.08% | 246 |
|
|
2025
Q2 | $1.66M | Sell |
68,393
-3,556
| -5% | -$82.9K | 0.09% | 240 |
|
|
2025
Q1 | $1.82M | Buy |
71,949
+18,900
| +36% | +$495K | 0.1% | 205 |
|
|
2024
Q4 | $1.41M | Sell |
53,049
-58,510
| -52% | -$1.59M | 0.07% | 281 |
|
|
2024
Q3 | $3.23M | Buy |
111,559
+621
| +0.6% | +$18.1K | 0.15% | 153 |
|
|
2024
Q2 | $3.1M | Buy |
110,938
+38,486
| +53% | +$1.06M | 0.15% | 145 |
|
|
2024
Q1 | $2.01M | Sell |
72,452
-79,256
| -52% | -$2.2M | 0.12% | 192 |
|
|
2023
Q4 | $4.37M | Sell |
151,708
-19,896
| -12% | -$601K | 0.25% | 114 |
|
|
2023
Q3 | $5.69M | Buy |
171,604
+35,095
| +26% | +$1.24M | 0.38% | 71 |
|
|
2023
Q2 | $5.01M | Buy |
136,509
+5,052
| +4% | +$197K | 0.35% | 74 |
|
|
2023
Q1 | $5.36M | Buy |
131,457
+25,265
| +24% | +$1.09M | 0.41% | 61 |
|
|
2022
Q4 | $5.44M | Buy |
106,192
+4,489
| +4% | +$215K | 0.45% | 48 |
|
|
2022
Q3 | $4.45M | Sell |
101,703
-26,464
| -21% | -$1.29M | 0.47% | 46 |
|
|
2022
Q2 | $6.72M | Sell |
128,167
-1,973
| -2% | -$101K | 0.61% | 28 |
|
|
2022
Q1 | $6.74M | Sell |
130,140
-8,889
| -6% | -$461K | 0.55% | 36 |
|
|
2021
Q4 | $8.21M | Sell |
139,029
-3,906
| -3% | -$194K | 0.59% | 30 |
|
|
2021
Q3 | $6.15M | Sell |
142,935
-4,417
| -3% | -$196K | 0.53% | 39 |
|
|
2021
Q2 | $5.77M | Buy |
147,352
+6,325
| +4% | +$246K | 0.51% | 45 |
|
|
2021
Q1 | $5.11M | Sell |
141,027
-5,369
| -4% | -$191K | 0.54% | 47 |
|
|
2020
Q4 | $5.39M | Buy |
146,396
+35,842
| +32% | +$1.31M | 0.74% | 29 |
|
|
2020
Q3 | $3.85M | Sell |
110,554
-736
| -0.7% | -$25.8K | 0.94% | 31 |
|
|
2020
Q2 | $3.45M | Buy |
111,290
+94,661
| +569% | +$3.22M | 1.06% | 24 |
|
|
2020
Q1 | $515K | Sell |
16,629
-510
| -3% | -$17.4K | 0.36% | 69 |
|
|
2019
Q4 | $637K | Sell |
17,139
-3,561
| -17% | -$127K | 0.36% | 65 |
|
|
2019
Q3 | $706K | Buy |
20,700
+2,398
| +13% | +$87.2K | 0.27% | 93 |
|
|
2019
Q2 | $752K | Buy |
18,302
+420
| +2% | +$16.7K | 0.3% | 80 |
|
|
2019
Q1 | $721K | Buy |
17,882
+301
| +2% | +$12.1K | 0.39% | 71 |
|
|
2018
Q4 | $728K | Buy |
+17,581
| New | +$730K | 0.49% | 61 |
|
Other funds holding PFE
Stratos Wealth Advisors's PFE Position: Q2 2026 in Review
Stratos Wealth Advisors reduced its Pfizer (PFE) stake by 4.4% in Q2 2026, selling an estimated $92.8K and leaving 76,265 shares worth $1.84M. The position accounts for 0.1% of the portfolio, ranked #199.
Stratos Wealth Advisors first reported a position in PFE in Q4 2018 and has held it in 31 quarters since. The position peaked at $8.21M in Q4 2021. 2,834 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Stratos Wealth Advisors held 76,265 shares of Pfizer worth $1.84M as of Q2 2026.
- Stratos Wealth Advisors sold 3,546 Pfizer shares in Q2 2026, an estimated $92.8K.
- Pfizer made up 0.1% of Stratos Wealth Advisors's portfolio in Q2 2026, its #199 holding.
- Stratos Wealth Advisors first reported a position in Pfizer in Q4 2018 and has held it in 31 quarters since.
- Stratos Wealth Advisors's Pfizer position peaked at $8.21M in Q4 2021.
- 2,834 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Stratos Wealth Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.